<DOC>
	<DOCNO>NCT02507388</DOCNO>
	<brief_summary>The purpose study assess systemic pharmacokinetics ( PK ) RTH258 subject ( Japanese non-Japanese ethnicity ) neovascular Age-Related Macular Degeneration ( AMD ) .</brief_summary>
	<brief_title>Safety Pharmacokinetics RTH258 Subjects With Age-Related Macular Degeneration</brief_title>
	<detailed_description>This study 2 arm 1:1 randomization . Randomization stratify Japanese ethnicity . Half subject arm Japanese ethnicity . The half subject arm non-Japanese . Subjects arms visit Day 84 .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Provide write informed consent ; Active choroidal neovascularization ( CNV ) lesion secondary AMD affect central subfield study eye ; Best Corrected Visual Acuity ( BCVA ) ≥ 23 letter study eye Baseline ; Other protocolspecified inclusion criterion may apply . Any active ocular infection inflammation ; Treatment aflibercept ( EYLEA® ) , bevacizumab ( AVASTIN® ) , ranibizumab ( LUCENTIS® ) , pegaptanib ( MACUGEN® ) , investigational drug neovascular AMD prior enrollment study , specify protocol ; Ocular surgery study eye , specify protocol ; Uncontrolled glaucoma study eye , specify protocol ; Use steroid study eye , specify protocol ; Medical condition may prevent study completion ; Pregnant nursing ( lactate ) woman ; Women childbearing potential unless use contraception ; Uncontrolled blood pressure , specify protocol ; Other protocolspecified exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>